Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Deferred Revenue (2016 - 2017)

Coherus Oncology (CHRS) has disclosed Current Deferred Revenue for 5 consecutive years, with $669000.0 as the latest value for Q1 2017.

  • Quarterly Current Deferred Revenue fell 98.65% to $669000.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was $669000.0 through Mar 2017, down 98.65% year-over-year, with the annual reading at $892000.0 for FY2016, 98.2% down from the prior year.
  • Current Deferred Revenue hit $669000.0 in Q1 2017 for Coherus Oncology, down from $892000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $61.3 million in Q2 2016 to a low of $162000.0 in Q1 2015.
  • Historically, Current Deferred Revenue has averaged $22.0 million across 5 years, with a median of $22.8 million in 2014.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 30537.65% in 2016 and later tumbled 98.65% in 2017.
  • Year by year, Current Deferred Revenue stood at $14.3 million in 2013, then soared by 59.63% to $22.8 million in 2014, then surged by 117.64% to $49.6 million in 2015, then crashed by 98.2% to $892000.0 in 2016, then dropped by 25.0% to $669000.0 in 2017.
  • Business Quant data shows Current Deferred Revenue for CHRS at $669000.0 in Q1 2017, $892000.0 in Q4 2016, and $1.4 million in Q3 2016.